CAMBRIDGE, Mass.--(BUSINESS WIRE)--SAGE Therapeutics, Inc., a biopharmaceutical company developing novel medicines to treat life-threatening, rare central nervous system (CNS) disorders, today announced the pricing of its initial public offering of 5,000,000 shares of common stock at a public offering price of $18.00 per share, before underwriting discounts. All of the common stock is being offered by SAGE. In addition, SAGE has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of common stock from SAGE at the public offering price to cover over-allotments, if any. The company’s shares are expected to begin trading on the NASDAQ Global Market on Friday, July 18, 2014 under the ticker symbol “SAGE.”
Help employers find you! Check out all the jobs and post your resume.
